• 2018 Pediatric Hematology/Oncology Fellows

    Wallace Bourgeois

    Wallace Bourgeois, MD

    Residency: Columbia University Medical Center/New York-Presbyterian Hospital
    Research interests: Acute lymphoblastic leukemia

    Wallace graduated from University of Chicago, earning a bachelor’s degree in religious studies. He then went on to New York University School of Medicine, where he investigated the mechanisms of drug resistance in pediatric acute lymphoblastic leukemia and graduated with honors. Wallace then completed his pediatrics residency at Columbia University Medical Center/New York-Presbyterian Hospital, where outside of his clinical training, he pursued further research in pediatric oncology and bone marrow transplant. Following his pediatrics residency, he was selected to serve an additional year as chief resident. In this role he was involved in managing the pediatric residency program and educating residents. During his time in fellowship, Wallace’s clinical work will entail the care of pediatric patients with hematologic diseases, oncologic diseases, and conditions requiring stem cell (bone marrow) transplantation.

    Kevin Campbell

    Kevin Campbell, MD

    Residency: Boston Combined Residency Program
    Research interests: Clinical oncology

    Kevin earned his bachelor’s degree in science in human biology from University of Kansas, where he also received his medical degree. As a medical student, Kevin analyzed daily fluctuations of lung function in multiple pediatric cystic fibrosis patients via home spirometry readings taken over the course of one year. As a Medical Student Scholar at Children’s Mercy Hospital, Kevin researched the mechanism of infiltration of human cytomegalovirus within the placenta during the first trimester. During his time in the Boston Combined Residency Program (BCRP), Kevin used recursive partitioning to identify associations between MYCN copy number and clinical features in patients with high-risk neuroblastoma to improve accuracy of risk stratification. He also retrospectively analyzed clinical and biological factors to determine markers of response and toxicity to mIBG therapy in high risk neuroblastoma patients. Kevin has an impressive background in leadership roles throughout his education and career. He was a Representative in the BCRP, as well as a Clinical Investigation Academy Leader from 2016-2017. Kevin was a Student Representative and Treasurer of the Medical Student Assembly while at the University of Kansas Medical School.

    Riaz Gillani

    Riaz Gillani, MD

    Residency: Boston Combined Residency Program
    Research interests: Solid tumor genomics

    Riaz graduated from Brown University, earning a bachelor’s degree in biomedical engineering before earning his medical degree from John Hopkins University School of Medicine. In the Park Laboratory at John Hopkins, Riaz contributed to the development of screening protocol for ESR1 mutations in patients with ER-positive metastatic breast cancer. He also worked with colleagues on a digital PCR-based assay for detection of ESR1 mutations in plasma samples. In the Stegmaier Laboratory during his time In the Boston Combined Residency Program, Riaz worked with CRISPR-Cas9 genomic screen data to analyze gene dependencies in neuroblastoma with the goal of identifying novel therapeutic targets. Riaz contributed to two peer-reviewed journal activities in Clinical Cancer Research and International Journal of Nanomedicine in 2016 and 2010, respectively. In 2016, Riaz was selected as the resident recipient of the Fred Lovejoy Housestaff Research and Education Grant, which funded neuroblastoma research. For his commitment to community service, Riaz was awarded the Yat K. Tow Prize for Public Service while at Brown University.

    Kirsty Hillier

    Kirsty Hillier, MD

    Residency: Baylor College of Medicine / Texas Children’s Hospital
    Research Interests: Translational basic science in solid tumors

    Kirsty earned her bachelor’s degree with honors in allied medicine at The Ohio State University College of Medicine, where she also earned her medical degree. Kirsty was selected to be chief resident at Baylor College of Medicine/Texas Children’s Hospital where she is a member of a number of committees including the Interviewing Subcommittee, House Staff Selection Committee, Pediatric Residency Curriculum & Evaluation Committee, and the Laboratory Medicine Committee. Kirsty was selected to be the supervising resident for pediatric interns during their very first inpatient rotation. She was a co-author for a publication in Pediatrics in 2017 and presented at the American Society of Pediatric Hematology and Oncology in 2018 . Her presentation was titled, “Factors Impacting Time to Engraftment in Patients with High Risk Neuroblastoma Following Stem Cell Transplant.” Kirsty’s clinical work during her time in fellowship will entail working with patients with hematologic and oncologic disorders in both the inpatient and outpatient clinical settings.

    Jessica Tsai

    Jessica Tsai, MD, PhD

    Residency: Boston Combined Residency Program
    Research Interests: Cell lineage related to solid tumors

    Jessica earned her bachelor’s degree in biological sciences from Stanford University where she also earned her PhD and medical degree. Jessica was extremely active in the Stanford community. She was a member of the Stanford School of Medicine Medical Scientist Training Program Admission Committee and co-chair of the Stanford Graduate Student Council. She was the recipient of the Stanford University Department of Biology Stephen Fox Award, which is awarded to the top undergraduate in the Department of Biology. During her time in the Boston Combined Residency Program, Jessica performed qualitative research understanding attitudes toward implicit bias and implicit bias training amongst pediatric residency program directors. She prepared and submitted a survey to the Association of Pediatric Program Directors and obtained an Institutional Review Board exempt approval from Boston Medical Center/Boston University School of Medicine. Prior to beginning her fellowship, Jessica was a postdoctoral fellow in the Walsh Laboratory as part of the Integrated Research Pathway. Jessica has contributed to a number of peer reviews journals including JAMA Pediatrics, Science, Nature Biotechnology, and PLoS Biology.

    Lara Wahlster

    Lara Wahlster, MD

    Residency: Boston Combined Residency Program
    Research Interests: Hematology, genetic blood disorders, and bone marrow transplantation

    Lara graduated summa cum laude from Ruprecht-Karls-University Heidelberg Germany in 2013. Her doctoral thesis examined intracellular protein folding and degradation mechanisms in neuronal models. After completing her pediatrics internship at Heidelberg University Children’s Hospital, Lara was awarded a Young Investigator Award by the Heidelberg Faculty of Science, which allowed her to pursue an early postdoctoral fellowship in stem cell research. As a postdoctoral fellow at Boston Children’s Hospital, she worked with George Daley, MD, PhD, using patient derived induced pluripotent stem cells for cellular engineering and modeling rare congenital blood disorders. Lara joined the Boston Combined Residency Program at Boston Children’s Hospital and Boston Medical Center in 2016, completing the accelerated research pathway as one of the physician scientist tracks within the program. She is interested in hematology, genetic blood disorders, and bone marrow transplantation. She plans to work with Vijay Sankaran, MD, PhD, as her mentor, using genomic tools to study hematopoiesis and hematopoietic stem cell biology.

  • Contact Us

    For questions regarding our fellowship program, please contact Fellowship Program Coordinator Sarah Johnson at 617-919-4242 or email sarah.johnson@childrens.harvard.edu.
  • A Long Legacy of Research and Treatment

    Dana-Farber/Boston Children's History

    More than 70 years ago, Dr. Sidney Farber refused to accept that childhood cancer was untreatable. His determination led to the development of chemotherapy and the first remissions of childhood leukemia.

  • Our Fellowship Programs

    Learn about our single-year clinical training programs as well as our new Early Oncology Drug Development Fellowship Program.